Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months #AHA2023 nejm.org/doi/full/10.10 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months #AHA2023 nejm.org/doi/full/10.10 Join the conversation
Retatrutide must be stored refrigerated at 2C to 8C, protected from light, and must not be frozen
By delivering the B12 directly into your muscle, the vitamin bypasses the digestive system entirely, allowing for complete and immediate absorption
For patients and providers, this means tirzepatide may be a better option for those seeking the greatest possible weight reduction or who have not achieved their goals with a GLP-1 agonist alone